A meta-analysis of 15 trials with 11,679 elderly type 2 diabetes patients found that combining GLP-1 receptor agonists with SGLT-2 inhibitors improved blood sugar, kidney function, cholesterol, and blood pressure without increasing side effects.
11,679 elderly patientsAcross 15 randomized controlled trials, the combination therapy showed benefits across every measured metabolic and cardiovascular marker
What the researchers found
GLP-1RA + SGLT-2i combination therapy in elderly T2DM patients reduced HbA1c by an additional 0.26%, improved eGFR, lowered LDL by 0.56 mmol/L, raised HDL by 0.18 mmol/L, and reduced systolic BP by 3.15 mmHg — all without increased adverse events.
Why it matters
Elderly diabetes patients are typically underrepresented in clinical trials, yet they carry the highest cardiovascular and renal risk. This meta-analysis specifically confirms that the most promising modern drug combination works effectively and safely in this vulnerable population.
The numbers in context
Meta-analysis of RCTs through May 2024 showing improvements in HbA1c, body weight, and blood pressure with the combination.
How the study worked
Systematic review and meta-analysis of 15 randomized controlled trials (11,679 patients) from Web of Science, Cochrane Library, Embase, and PubMed through May 2024. Analyzed using RevMan 5.3 software.
Who was studied
Elderly adults with type 2 diabetes mellitus
What this study cannot tell us
The definition of 'elderly' varied across included trials, and long-term outcomes beyond trial periods weren't assessed. The number of RCTs specifically targeting elderly populations remains limited. Individual drug combinations within the classes may differ in effect.
How to read the evidence
Strong evidence from a meta-analysis of 15 randomized controlled trials — the highest tier of clinical evidence. Results were statistically significant across all measured outcomes.
When this study was published
Published in 2024, with literature search through May 2024; reflects the most current evidence available.
The bigger picture
The combination of GLP-1 agonists and SGLT-2 inhibitors is increasingly seen as the gold standard for type 2 diabetes management because it addresses blood sugar, weight, cardiovascular risk, and kidney protection simultaneously. This evidence helps extend that confidence to older adults, who stand to benefit most from these multi-system protections.
Questions still open
- Does the combination therapy reduce hard cardiovascular endpoints (heart attacks, strokes) in the elderly, or just surrogate markers?
- Which specific GLP-1RA and SGLT-2i pairings work best together in older adults?
- How does this combination perform in elderly patients with advanced kidney disease or frailty?
Common questions
Is it safe for elderly patients to take both a GLP-1 drug and an SGLT-2 inhibitor together?
What are the practical benefits beyond blood sugar control?
Read the original research
Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.
American journal of translational research, 16(11), 6852-6866
Citation
Wu, Yaping; Yang, Zhenxing; Cao, Qingqing. (2024). Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.. American journal of translational research, 16(11), 6852-6866. https://doi.org/10.62347/MCEE4840